Do proton pump inhibitors modulate the efficacy of anti-PD-1/PD-L1 therapy? A retrospective study

被引：28
|
作者：
Mukherjee, Sarbajit [1 ]
Ibrahimi, Sami [1 ]
Khalid, Bilal [1 ]
Roman, Darwin [2 ]
Zhao, Daniel [3 ]
Aljumaily, Raid [1 ]
机构：
[1] Univ Oklahoma, Hlth Sci Ctr, Dept Med, Div Hematol Oncol, Oklahoma City, OK USA
[2] Univ Oklahoma, Hlth Sci Ctr, Dept Med, Oklahoma City, OK USA
[3] Univ Oklahoma, Hlth Sci Ctr, Dept Biostat & Epidemiol, Oklahoma City, OK USA
来源：
JOURNAL OF ONCOLOGY PHARMACY PRACTICE | 2019年 / 25卷 / 03期
关键词：
D O I：
10.1177/1078155218771152
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：762 / 764
页数：3
相关论文
共 50 条
  • [41] Progresses and Perspectives of Anti-PD-1/PD-L1 Antibody Therapy in Head and Neck Cancers
    Yang, Bo
    Liu, Tingjun
    Qu, Yang
    Liu, Hangbo
    Zheng, Song Guo
    Cheng, Bin
    Sun, Jianbo
    FRONTIERS IN ONCOLOGY, 2018, 8
  • [42] Rationale of combination of anti-PD-1/PD-L1 antibody therapy and radiotherapy for cancer treatment
    Sato, Hiro
    Okonogi, Noriyuki
    Nakano, Takashi
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2020, 25 (05) : 801 - 809
  • [43] Burgeoning Exploration of the Role of Natural Killer Cells in Anti-PD-1/PD-L1 Therapy
    Bai, Rilan
    Cui, Jiuwei
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [44] The Value of PD-L1 Expression in Predicting the Efficacy of Anti-PD-1 or Anti-PD-L1 Therapy in Patients with Cancer: A Systematic Review and Meta-Analysis
    Chen, Xiao-Jiang
    Yuan, Shu-Qiang
    Duan, Jin-Ling
    Chen, Yong-Ming
    Chen, Shi
    Wang, Yun
    Li, Yuan-Fang
    DISEASE MARKERS, 2020, 2020
  • [45] Anti-PD-1/PD-L1 therapy for colorectal cancer: Clinical implications and future considerations
    Chen, Xiang
    Chen, Ling-Juan
    Peng, Xiao-Fei
    Deng, Ling
    Wang, Yan
    Li, Jiu-Jiang
    Guo, Dong-Li
    Niu, Xiao-Hua
    TRANSLATIONAL ONCOLOGY, 2024, 40
  • [46] Exosomal PD-L1 and T lymphocyte status predict the effect of anti-PD-1 therapy
    Zhang, C.
    Qu, X.
    Fan, Y.
    Zhang, M.
    Che, X.
    Hou, K.
    Liu, Y.
    EUROPEAN JOURNAL OF IMMUNOLOGY, 2019, 49 : 1753 - 1753
  • [47] Anti-PD-1/PD-L1 therapy for infectious diseases: learning from the cancer paradigm
    Rao, Martin
    Valentini, Davide
    Dodoo, Ernest
    Zumla, Alimuddin
    Maeurer, Markus
    INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2017, 56 : 221 - 228
  • [48] Efficacy and safety of adjuvant therapy with PD-1/PD-L1 inhibitors in cancer
    Mo, Dun-Chang
    Liang, Zi-Yu
    Chen, Long
    Huang, Jian-Feng
    Luo, Peng-Hui
    Wang, Han-Lei
    EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2022, 24 (06)
  • [49] Safety and Efficacy of Anti-PD-1/PD-L1 Inhibitors Compared With Docetaxel for NSCLC: A Systematic Review and Meta-Analysis
    Ma, Long
    Jin, Gang
    Yao, Keying
    Yang, Yi
    Chang, Ruitong
    Wang, Wenhao
    Liu, Jiawei
    Zhu, Zijiang
    FRONTIERS IN PHARMACOLOGY, 2021, 12
  • [50] ASSESSING THE IMPACT OF ANTI-PD-1/PD-L1 INHIBITORS ON CANCER CARE HEALTH AND BUDGET IN GREECE
    Ktena, D.
    Dalakaki, E.
    Dimitriadis, I
    Mountain, G.
    Hughes, R.
    Clarke-Melville, S.
    Roediger, A.
    Naoum, P.
    Athanasakis, K.
    VALUE IN HEALTH, 2022, 25 (12) : S267 - S267
12345